Light beam targets cancer in new head & neck treatment trial
Disease control
Recruiting now
This study is testing whether a new light-activated drug (ASP-1929) works better when combined with an immunotherapy drug (pembrolizumab) for people whose head and neck cancer has come back locally. It will compare this new combination to the current standard treatments. The main…
Phase: PHASE3 • Sponsor: Rakuten Medical, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC